COgnitioN With VERiciGuat Evaluation in Heart Failure

Recruiting Phase 2 Interventional Study
Heart Failure Cognitive Impairment
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
120 (estimated)
Sponsor
University of Alberta · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Adult patients 2. Established chronic heart failure (≥ 6 months) 3. Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25). Exclusion Criteria: 1. Patients who have contraindications for sGC…
Contacts

Justin Ezekowitz, MBBCh, MSc

780-492-0712

jae2@ualberta.ca

CONTACT

Amanda Perreault, MSc

780-492-5484

aperreau@ualberta.ca

CONTACT